Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 64, Issue -, Pages S365-S378Publisher
IOS PRESS
DOI: 10.3233/JAD-179917
Keywords
3xTg-AD; amyloid-beta; animal models; comorbidities; inflammation; stem cell therapy; synaptic loss; tau
Categories
Funding
- Alzheimer's Association [NIRG-15-363477, AARF-16-440760]
- Larry Hillblom Foundation [2013-A-016-FEL, 2016-A-016-FEL]
- National Institute of Health (NIH) NIH/NIA [AG027544, AG00538, AG054 884]
- Bright Focus Foundation [A201 5535S]
Ask authors/readers for more resources
Alzheimer's disease (AD) impairs memory and causes significant cognitive deficits. The disease course is prolonged, with a poor prognosis, and thus exacts an enormous economic and social burden. Over the past two decades, genetically engineered mouse models have proven indispensable for understanding AD pathogenesis, as well as for discovering new therapeutic targets. Here we highlight significant studies from our laboratory that have helped advance the AD field by elucidating key pathogenic processes operative in AD and exploring a variety of aspects of the disease which may yield novel therapeutic strategies for combatting this burdensome disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available